Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock

Core Insights - Nuvation Bio Inc. (NYSE:NUVB) is recognized as one of the best stocks to buy according to billionaire David Abrams, with a stable position in Abrams Capital Management's portfolio since Q1 2021, holding 3.81 million shares [1] - The company is focused on developing cancer treatment candidates, with its lead product IBTROZI (taletrectinib) being a ROS1 inhibitor for ROS1+ non-small cell lung cancer [1] - Recent strategic advances include approvals and partnerships for IBTROZI in China and Japan, and a new partnership with Eisai for European markets, aiming for European approval submission in H1 2026 [1] Financial Performance - In Q4 2025, Nuvation Bio reported $41.9 million in revenue, with $15.7 million attributed to IBTROZI [3] - The company treated 432 new patients with IBTROZI from approval through year-end, indicating its growing adoption in both TKI-naive and pretreated populations [3] - Management expressed confidence in continued growth of first-line patients and the expanding presence of IBTROZI, although specific revenue guidance for 2026 was not provided [3]